

**Updated: 27.01. 2022**

Therapeutic intervention studies that actively include patients in Norway.

**DEN-STEM (Phase 2-3)**

Description: Randomized vaccine study on glioblastoma patients (primary diagnosis) Place: Oslo University Hospital

Information:

<https://oslo-universitetssykehus.no/kliniske-studier/glioblastoma-standardbehandling-motstandardbehandling-med-immunterapi-den-stem>

Contact: [uxvieb@ous-hf.no](mailto:uxvieb@ous-hf.no)

**IMPRESS-Losartan (Phase 2)**

Description: Glioblastoma patients (primary diagnosis). See if the drug Losartan affects the tumor by opening up the blood vessels, thereby improving the effect of usual cancer treatment.

Place: Oslo University Hospital Contact: [pebra@ous-hf.no](mailto:pebra@ous-hf.no)

**Surgery with a margin**

Description: Glioblastoma patients (primary diagnosis). In carefully selected patients, more of the cancer cells that infiltrate normal brain tissue will be removed, thereby improving the prognosis.

Location: National

Contact: [legepost@gmail.com](mailto:legepost@gmail.com)

**VIGAS 2 (Phase 2)**

Description: Glioblastoma patients (primary diagnosis). Antiviral treatment of patients with Valganciclovir

Location: Oslo University Hospital, Stavanger University Hospital Contact: [pebra@ous-hf.no](mailto:pebra@ous-hf.no)

**BORTEM (Phase 2)**

Description: Treatment of Glioblastoma after relapse with Bortezomid in combination with chemotherapy.

Location: National

Contact: [dorota@goplen.net](mailto:dorota@goplen.net)

**Impress-Losartan (Phase 2)**

Description: Treatment of Glioblastoma after relapse. See if the drug losartan affects the tumor by opening up the blood vessels, thereby improving the effect of usual cancer treatment.

Place: Oslo University Hospital Contact: [pebra@ous-hf.no](mailto:pebra@ous-hf.no)

**SAS-GKRS (Phase 1)**

Description: Treatment of Glioblastoma after relapse. Stereotactic radiotherapy in combination with the drug Sulfasalazine.

Place: Haukeland University Hospital

Contact: [bente.sandvei.skeie@helse-bergen.no](mailto:bente.sandvei.skeie@helse-bergen.no)

**ISM-GBM (Phase 1)**

Description: Treatment of Glioblastoma after relapse. Personalized treatment based on drug screening for cancer stem cells.

Place: Oslo University Hospital

Contact: [uxvieb@ous-hf.no](mailto:uxvieb@ous-hf.no)

**Optimal TTF-2 (Phase 2)**

Description: Treatment of Glioblastoma after relapse. Tumor Treating Fields in combination with surgery.

Location: St Olav's Hospital Contact: [ole.solheim@ntnu.no](mailto:ole.solheim@ntnu.no)

**PRO-GLIO (Phase 3)**

Description: Treatment of Glioblastoma after relapse using Proton Therapy. Place: Oslo University Hospital, Haukeland University Hospital

Contact: [pebra@ous-hf.no](mailto:pebra@ous-hf.no)

**PNET 5 (Phase 2-3)**

Description: Treatment of medulloblastoma using radiation therapy in combination with carboplatin.

Location: National

Contact: [pebra@ous-hf.no](mailto:pebra@ous-hf.no)

**IMPRESS Norway (Phase 2)**

Description: Basket study (includes several different cancer tumours). Personalized treatment based on genetic analyzes of the tumour.

Location: National

Contact: Local Teams at various hospitals.

**MK3475-158 (Phase 2)**

Description: Basketball study (covers several different cancers). clinical trial with pembrolizumab (MK-3475) to evaluate biomarkers in patients with advanced solid tumors

Location: Oslo University Hospital, Haukeland University Hospital Contact: [uxtour@ous-hf.no](mailto:uxtour@ous-hf.no)

**NAVIGATE (Phase 2)**

Description: Basket study (includes several different cancer tumours). Treatment of cancer patients who have a particular gene change with Larotrectinib.

Location: Oslo University Hospital Contact: [uxtour@ous-hf.no](mailto:uxtour@ous-hf.no)